Need HER2+ Testing in CRC; Trastuzumab Deruxtecan Shows Benefit Need HER2+ Testing in CRC; Trastuzumab Deruxtecan Shows Benefit

Durable responses seen in phase 2 trial of trastuzumab deruxtecan in patients with heavily pretreated HER2-positive colorectal cancer suggests that HER2 testing become standard of care, argues expert.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news